Naslov
HLA antibody monitoring after kidney transplantation

Autori
Kovačević Cuculić, T ; Katalinić, N ; Orlić, L ; Kurtović, H ; Duhović, M ; Šimac Sušanj, I ; Balen, S

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
HLA / Steven G. E. Marsh, UK - Oxford : John Wiley & Sons, 2018, 384-384

Skup
32nd European Immunogenetics and Histocompatibility Conference (EFI) ; 25th Annual Meeting of the Italian Society for Immunogenetics and Transplantation Biology (AIBT)

Mjesto i datum
Venecija, Italija, 09.05.2018. - 12.05.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
HLA antibodies, DSA, kidney transplantation

Sažetak
Introduction: Antibody-mediated rejection (ABMR) is the most common cause of kidney allograft failure. Renal transplant recipients with preexisting donor-specific antibodies (DSA) or patients who develop de novo DSA after transplantation are in risk of ABMR. Therefore, HLA antibody monitoring before and after transplantation as well may help to identify patients at risk of graft loss. Method: In Tissue Typing Laboratory, CHC Rijeka HLA antibody screening after kidney transplantation has been routinely tested on the day of transplantation and one month after. From December 2015, we started to perform posttransplantion monitoring of HLA antibodies at months 1, 3, 6 and 12. This retrospective analysis included HLA antibody screening results for 36 patients that have been transplanted from December 2015 until February 2017. All patient's sera have been tested by CDC and Luminex (Immucor) techniques. Results: Before transplantation, 30 (83.3%) patients were negative and 6 (16.7%) CDC and/or LUM positive. Among negative patients, 26 (72, 2%) remained negative, while 4 (11, 1%) became positive after transplantion. In one patient, class II DSA were detected 3 months after transplantation and 9 months later he had graft loss. In other patient, class II non-DSA were detected 6 months after transplantation without signs of graft dysfunction. Class I/II non-DSA were detected in two patients 12 months after transplantation associated with transitory graft dysfunction. Among pretransplant immunized patients, one has developed class II DSA 3 months after transplantation along with graft dysfunction. Adjustment od immunosuppressive therapy was successfull. Conclusion: These results suggest that development of de novo DSA so as non-DSA may have detrimental effect on graft function after kidney transplantation, but for the reliable conclusions posttransplantion monitoring needs to be continued including larger number of patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA